Introduction
Recurrent respiratory papillomatosis (RRP) can represent a significant clinical challenge in the world of paediatric airway disease. The disease's severity and progression may vary and therefore necessitate a constantly evolving and evidence-based approach. The most recently pioneered arm of managing RRP is the use of VEGF monoclonal antibody, bevacizumab. This is a challenging case of aggressive paediatric RRP that has required the use of all available treatment modalities.
The patient
A 10-year-old girl, with significant medical and neurological history, was diagnosed with aggressive airway-obstructing RRP at 2 years of age. Over the years, she has undergone various RRP treatments, which have failed to control her disease progression.
The primary diagnoses interventions and outcomes
Following failure of traditional management adjuncts, and due to the increasing frequency and need for surgical debridement, an evidence-based decision was made to administer bevacizumab. This was administered locally, and resulted in temporary improvement. Therefore, systemic bevacizumab was eventually sought with excellent outcomes within the first year.
Conclusion
Aggressive RRP, particularly in the presence of other comorbidities, presented a management dilemma in this case. The aggressive nature of the disease necessitated out-of-box thinking, seeking evidence from the literature, and a consultation with national experts on the application of alternative treatment options such as intralesional and, subsequently, systemic bevacizumab. The latter has so far produced a yearlong excellent control of the condition. The article discusses suggestions for multicentre research into this treatment modality, and for the standardisation its administration protocols in adults and children.
扫码关注我们
求助内容:
应助结果提醒方式:
